Oragenics Inc
OGEN1.250USD
0.000
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
26.84MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Oragenics Inc Unternehmen
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.
Unternehmensinformationen
BörsenkürzelOGEN
Name des UnternehmensOragenics Inc
IPO-datumJul 09, 2003
CEOMs. Janet Huffman
Anzahl der mitarbeiter3
WertpapierartOrdinary Share
GeschäftsjahresendeJul 09
Addresse1990 Main Street
StadtSARASOTA
BörseNYSE American Consolidated
LandUnited States of America
Postleitzahl34236
Telefon18132867900
Websitehttps://www.oragenics.com/
BörsenkürzelOGEN
IPO-datumJul 09, 2003
CEOMs. Janet Huffman
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
1.16K
--
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Executive Chairman of the Board
Executive Chairman of the Board
849.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
--
--
Dr. James Kelly, M.D.
Dr. James Kelly, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Mr. Tirth T. Patel
Mr. Tirth T. Patel
Vice President
Vice President
--
--
Dr. William (Frank) Peacock, M.D.
Dr. William (Frank) Peacock, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
1.16K
--
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Executive Chairman of the Board
Executive Chairman of the Board
849.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
--
--
Dr. James Kelly, M.D.
Dr. James Kelly, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Jul 29
Aktualisiert: Tue, Jul 29
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Five Narrow Lane LP
9.99%
Cassidy (Bruce A Sr)
1.44%
Geode Capital Management, L.L.C.
0.34%
Two Sigma Investments, LP
0.18%
Telling (Frederick W)
0.14%
Other
87.91%
Aktionäre
Aktionäre
Anteil
Five Narrow Lane LP
9.99%
Cassidy (Bruce A Sr)
1.44%
Geode Capital Management, L.L.C.
0.34%
Two Sigma Investments, LP
0.18%
Telling (Frederick W)
0.14%
Other
87.91%
Aktionärstypen
Aktionäre
Anteil
Corporation
10.05%
Individual Investor
2.06%
Investment Advisor/Hedge Fund
0.35%
Investment Advisor
0.30%
Hedge Fund
0.21%
Venture Capital
0.10%
Other
86.93%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
51
25.35K
3.08%
-29.87K
2025Q1
54
104.53K
39.81%
+67.24K
2024Q4
61
3.11M
25.46%
+2.05M
2024Q3
59
1.22M
18.08%
+226.05K
2024Q2
58
1.45M
24.58%
+674.78K
2024Q1
57
1.51M
26.60%
+861.00K
2023Q4
59
1.13M
28.10%
+795.74K
2023Q3
58
266.28K
10.68%
+19.84K
2023Q2
53
93.56K
4.68%
-159.82K
2023Q1
59
99.61K
5.08%
-139.03K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Cassidy (Bruce A Sr)
11.82K
1.44%
+3.00
+0.03%
Mar 21, 2025
Geode Capital Management, L.L.C.
2.83K
0.34%
+1.54K
+120.42%
Mar 31, 2025
Two Sigma Investments, LP
1.45K
0.18%
+224.00
+18.35%
Mar 31, 2025
Telling (Frederick W)
1.16K
0.14%
--
--
Mar 21, 2025
Koski (Robert C)
931.00
0.11%
--
--
Mar 21, 2025
Dunton (Alan W)
854.00
0.1%
--
--
Mar 21, 2025
Pope (Charles L)
849.00
0.1%
--
--
Mar 21, 2025
Murphy (Kimberly M)
833.00
0.1%
--
--
Mar 21, 2025
XTX Markets LLC
828.00
0.1%
-470.00
-36.21%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Datum
Art
Verhältnis
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
